欢迎来到OAJRC平台!

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据:

Open Access Article

International Journal of Obstetrics and Gynecology. 2022; 2: (1) ; 68-70 ; DOI: 10.12208/j. ijog.20220020.

Clinical analysis of leuprorelin combined with mifepristone tablets in the treatment of adenomyosis
亮丙瑞林联合米非司酮片治疗腺肌症的临床治疗效果分析

作者: 吴敏*,

云南省曲靖市宣威求实医院 云南曲靖

*通讯作者: 吴敏,单位:云南省曲靖市宣威求实医院 云南曲靖;

发布时间: 2022-06-22 总浏览量: 30

摘要

目的 分析对腺肌症患者施以亮丙瑞林、米非司酮片联合治疗的效果。方法 分析对象选择于2020.2~2021.2就诊于我院的腺肌症患者78例,随机数字法予以分组,施以亮丙瑞林、米非司酮片联合治疗的39例患者分入治疗组,施以亮丙瑞林单用治疗的39例患者分入对照组,对治疗效果(痛经情况、子宫体积、应激因子)进行对比和分析。结果 与对照组对比,治疗组患者各个时段(治疗后3个月、半年、1年)痛经评分均明显较低(P<0.05);与对照组对比,治疗组治疗后子宫体积明显较小(P<0.05);与对照组对比,治疗组患者治疗后应激因子(IL-6、IL-2、CRP)明显较好(P<0.05)。结论 对腺肌症患者施以亮丙瑞林、米非司酮片联合治疗效果突出,可改善患者痛经情况,减少子宫体积,减轻应激因子,建议推广。

关键词: 腺肌症;亮丙瑞林;米非司酮;痛经;应激因子

Abstract

Objective To analyze the effect of leuproline and mifepristone tablets on patients with adenomyosis.
Methods 78 patients with adenomyosis treated in our hospital from February 2020 to February 2021 were randomly divided into two groups. 39 patients treated with leuprorelin and mifepristone tablets were divided into the treatment group and 39 patients treated with leuprorelin alone were divided into the control group. The treatment effects (dysmenorrhea, uterine volume and stress factors) were compared and analyzed.
Results compared with the control group, the dysmenorrhea scores of patients in the treatment group were significantly lower in each period (3 months, 6 months and 1 year after treatment) (P < 0.05); Compared with the control group, the volume of uterus in the treatment group was significantly smaller after treatment (P < 0.05); Compared with the control group, the stress factors (IL-6, IL-2, CRP) in the treatment group were significantly better (P < 0.05).
Conclusion   the combined treatment of leuproline and mifepristone tablets in patients with adenomyosis has outstanding effect, which can improve the dysmenorrhea, reduce the uterine volume and reduce stress factors. It is recommended to popularize it.

Key words: Adenomyosis; Leuprorelin; Mifepristone; Dysmenorrhea; Stress factor

参考文献 References

[1] 田勇,冉林,谷新,柯凤梅,税成愈.曼月乐联合亮丙瑞林治疗子宫腺肌症合并卵巢子宫内膜异位囊肿的临床效果评价[J].现代消化及介入诊疗,2020(S01):0294-0294.

[2] 许芳. 醋酸亮丙瑞林联合曼月乐治疗子宫腺肌症的临床效果分析[J]. 药品评价,2020,17(4):67-68. 

[3] 王斌斌. 醋酸亮丙瑞林联合曼月乐治疗子宫腺肌症的临床效果研究[J]. 中国社区医师,2021,37(23):53-54,57.

[4] 马艳,倪观太,臧学利,等. 亮丙瑞林治疗弥漫型子宫腺肌症患者的临床研究[J]. 中国临床药理学杂志,2021,37(18):2409-2412. 

[5] 彭慧英. 亮丙瑞林联合左炔诺孕酮宫内节育系统治疗子宫腺肌症的疗效分析[J]. 当代医学,2020,26(34):21-23.

[6] 李娅娜.亮丙瑞林联合曼月乐治疗子宫腺肌症的临床疗效观察[J].中国处方药,2020,18(6):124-126.

[7] 刘红,夏敬梅,李相相. 探究亮丙瑞林与曼月乐联合应用于子宫腺肌症的临床价值[J]. 系统医学,2021,6(9):118-120.

[8] 耿鹏, 刘阳, 张法丽. 亮丙瑞林联合曼月乐治疗子宫腺肌症疗效观察[J]. 中国医药科学, 2016, 6(19):4.

[9] 曹月琴. 亮丙瑞林联合曼月乐治疗子宫腺肌症40例临床观察[J]. 中外女性健康研究, 2016(13):2.

引用本文

吴敏, 亮丙瑞林联合米非司酮片治疗腺肌症的临床治疗效果分析[J]. 国际妇产科研究, 2022; 2: (1) : 68-70.